A randomised controlled trial (Li, 2021) indicated that modified SLBZS combined with azithromycin significantly reduced serum concentrations of tumour necrosis factor-α (TNF-α), interleukin-8 (IL-8), IL-6, and CD8+, while enhancing levels of CD3+ and CD4+, thereby promoting lesion absorption and the alleviation of lung rales in paediatric patients with Mycoplasma pneumonia. The gene discussed is CXCL8; the disease is Mycoplasma pneumoniae pneumonia.